EA017278B9 - Соединения азаиндазола и способы применения - Google Patents

Соединения азаиндазола и способы применения

Info

Publication number
EA017278B9
EA017278B9 EA200800100A EA200800100A EA017278B9 EA 017278 B9 EA017278 B9 EA 017278B9 EA 200800100 A EA200800100 A EA 200800100A EA 200800100 A EA200800100 A EA 200800100A EA 017278 B9 EA017278 B9 EA 017278B9
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compounds
ccr1
antagonists
azaindazole compounds
Prior art date
Application number
EA200800100A
Other languages
English (en)
Other versions
EA200800100A1 (ru
EA017278B1 (ru
Inventor
Пенгли Чжанг
Эндрю М.К. Пеннелл
Джон Дж. Ким Райт
Вей Чэн
Манмохан Р. Лелети
Уандонг Ли
Лианфа Ли
Юань Ксу
Original Assignee
Кемосентрикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37595833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA017278(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Кемосентрикс, Инк. filed Critical Кемосентрикс, Инк.
Publication of EA200800100A1 publication Critical patent/EA200800100A1/ru
Publication of EA017278B1 publication Critical patent/EA017278B1/ru
Publication of EA017278B9 publication Critical patent/EA017278B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Описываются соединения общей формулы Ia и Ibкоторые действуют как потенциальные антагонисты рецептора CCR1 и имеют противовоспалительную активность in vivo. Соединения, в целом, представляют собой арилпиперазиновые производные и применимы в фармацевтических композицях, способах лечения опосредуемых CCR1 заболеваний и как контрольные соединения в анализах для идентификации конкурентных антагонистов CCR1.
EA200800100A 2005-06-22 2006-06-22 Соединения азаиндазола и способы применения EA017278B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69352505P 2005-06-22 2005-06-22
PCT/US2006/024313 WO2007002293A2 (en) 2005-06-22 2006-06-22 Azaindazole compounds and methods of use

Publications (3)

Publication Number Publication Date
EA200800100A1 EA200800100A1 (ru) 2008-06-30
EA017278B1 EA017278B1 (ru) 2012-11-30
EA017278B9 true EA017278B9 (ru) 2013-01-30

Family

ID=37595833

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800100A EA017278B9 (ru) 2005-06-22 2006-06-22 Соединения азаиндазола и способы применения

Country Status (27)

Country Link
US (2) US7524845B2 (ru)
EP (1) EP1906965B1 (ru)
JP (1) JP5275794B2 (ru)
KR (2) KR20140026644A (ru)
CN (1) CN101242839B (ru)
AU (1) AU2006262122B2 (ru)
BR (1) BRPI0612112A8 (ru)
CA (1) CA2612552C (ru)
DK (1) DK1906965T3 (ru)
EA (1) EA017278B9 (ru)
ES (1) ES2543714T3 (ru)
HK (1) HK1124241A1 (ru)
HR (1) HRP20150832T1 (ru)
HU (1) HUE025476T2 (ru)
IL (1) IL188050A (ru)
MA (1) MA29568B1 (ru)
MX (1) MX2007015917A (ru)
NO (1) NO340621B1 (ru)
NZ (1) NZ564258A (ru)
PL (1) PL1906965T3 (ru)
PT (1) PT1906965E (ru)
RS (1) RS54206B1 (ru)
SG (2) SG162807A1 (ru)
SI (1) SI1906965T1 (ru)
UA (1) UA95777C2 (ru)
WO (2) WO2007002667A2 (ru)
ZA (2) ZA200800309B (ru)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
SI1906965T1 (sl) 2005-06-22 2015-09-30 Chemocentryx, Inc. Azaindolne spojine in postopki uporabe
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US20080032960A1 (en) 2006-04-04 2008-02-07 Regents Of The University Of California PI3 kinase antagonists
US20090252779A1 (en) * 2006-06-22 2009-10-08 Chemocentryx, Inc. Azaindazole compounds and methods of use
PL2155712T3 (pl) 2007-05-22 2017-02-28 Chemocentryx, Inc. 3-(imidazolilo)-pirazolo[3,4-b]pirydyny
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
NZ613219A (en) 2008-01-04 2014-11-28 Intellikine Llc Heterocyclic containing entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8008327B2 (en) 2008-04-29 2011-08-30 Boehringer Ingelheim International Gmbh Indazole compounds as CCR1 receptor antagonists
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
PL2323663T3 (pl) 2008-09-11 2015-08-31 Chemocentryx Inc 4-amino-3-(imidazolilo)-pirazolo[3,4,-d]pirymidyny
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
CN102227425A (zh) 2008-09-26 2011-10-26 贝林格尔·英格海姆国际有限公司 作为ccr1受体拮抗剂的氮杂吲唑化合物
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
AU2009308687A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
US8362249B2 (en) * 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
WO2010126811A1 (en) * 2009-04-27 2010-11-04 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
MX2012001520A (es) * 2009-08-03 2012-06-01 Acraf Proceso para la preparacion de 1-bencil-3-hidroximetil-1h-indazol y sus derivados e intermediarios de magnesio requeridos.
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
SI2491028T1 (sl) * 2009-10-21 2014-03-31 Boehringer Ingelheim International Gmbh Indazolne in pirazolopiridinske spojine kot antagonisti receptorja CCR1
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
EP2563787B1 (en) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Azaindazole amide compounds as ccr1 receptor antagonists
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2654750B1 (en) 2010-12-20 2017-03-08 Pfizer Inc Novel fused pyridine compounds as casein kinase inhibitors
JP5684406B2 (ja) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのピラゾロピペリジン化合物
UA115767C2 (uk) 2011-01-10 2017-12-26 Інфініті Фармасьютікалз, Інк. Способи отримання ізохінолінонів і тверді форми ізохінолінонів
GB2488752A (en) * 2011-02-21 2012-09-12 Sony Dadc Austria Ag Microfluidic Device
CN106619647A (zh) 2011-02-23 2017-05-10 因特利凯有限责任公司 激酶抑制剂的组合及其用途
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
EP2751112B1 (en) 2011-09-02 2019-10-09 The Regents of The University of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
JP5796130B2 (ja) 2011-09-14 2015-10-21 プロクシマゲン リミテッド 新規な酵素阻害剤化合物
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
AU2013355054B2 (en) * 2012-12-07 2017-08-24 Chemocentryx, Inc. Diazole lactams
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN105801574A (zh) * 2014-12-31 2016-07-27 上海药谷药业有限公司 一种1H-吡唑并[3,4-b]吡啶化合物的制备方法
ES2709985T3 (es) 2015-01-15 2019-04-22 Idorsia Pharmaceuticals Ltd Derivados de hidroxialquil-piperazina como moduladores del receptor CXCR3
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
JP2019510832A (ja) * 2016-04-07 2019-04-18 ケモセントリクス，インコーポレーテッド Ｐｄ−１阻害剤又はｐｄ−ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20190033526A (ko) 2016-06-24 2019-03-29 인피니티 파마슈티칼스, 인코포레이티드 병용 요법
CN108570049A (zh) * 2018-07-24 2018-09-25 上海毕得医药科技有限公司 一种6-氯-1氢-吡唑并[3,4-b]吡啶的合成方法
CN108794470B (zh) * 2018-07-25 2020-06-26 上海毕得医药科技有限公司 一种6-肼基-1H-吡唑并[3,4-b]吡啶及其下游产品的合成方法
CN110343103A (zh) * 2019-07-04 2019-10-18 深圳市格物致欣化学技术有限公司 吡唑并吡啶类化合物及其制备方法
WO2021007386A1 (en) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes as pd-l1 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082571A1 (en) * 2002-06-12 2004-04-29 Chemocentryx, Inc. Substituted piperazines
RU2003106191A (ru) * 2000-09-06 2004-07-27 Орто-Макнейл Фармасьютикал, Инк. Способ лечения аллергии с использованием замещенных пиразолов
EA200400466A1 (ru) * 2001-10-22 2004-08-26 Пфайзер Продактс Инк. Производные пиперазина с антагонистической активностью к рецептору ccr1
RU2003107016A (ru) * 2000-08-14 2004-11-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Замещенные пиразолы

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862079D1 (en) * 1977-10-26 1982-12-09 Wellcome Found Imidazoline derivatives and salts thereof, their synthesis, pesticidal formulations containing the imidazolines, preparation thereof and their use as pesticides
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
US4927942A (en) * 1988-12-15 1990-05-22 Texaco Chemical Co. Method for the preparation of imidazoles
RU2286343C2 (ru) * 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP4845873B2 (ja) * 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
SI1906965T1 (sl) 2005-06-22 2015-09-30 Chemocentryx, Inc. Azaindolne spojine in postopki uporabe

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003107016A (ru) * 2000-08-14 2004-11-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Замещенные пиразолы
RU2003106191A (ru) * 2000-09-06 2004-07-27 Орто-Макнейл Фармасьютикал, Инк. Способ лечения аллергии с использованием замещенных пиразолов
EA200400466A1 (ru) * 2001-10-22 2004-08-26 Пфайзер Продактс Инк. Производные пиперазина с антагонистической активностью к рецептору ccr1
US20040082571A1 (en) * 2002-06-12 2004-04-29 Chemocentryx, Inc. Substituted piperazines

Also Published As

Publication number Publication date
UA95777C2 (en) 2011-09-12
HK1124241A1 (en) 2009-07-10
AU2006262122A1 (en) 2007-01-04
KR101418024B1 (ko) 2014-07-16
KR20140026644A (ko) 2014-03-05
ZA200901845B (en) 2011-03-30
IL188050A (en) 2015-10-29
BRPI0612112A8 (pt) 2017-12-26
JP5275794B2 (ja) 2013-08-28
CN101242839A (zh) 2008-08-13
NO340621B1 (no) 2017-05-15
WO2007002293A2 (en) 2007-01-04
SG10201504801VA (en) 2015-07-30
KR20080039850A (ko) 2008-05-07
SG162807A1 (en) 2010-07-29
US7524845B2 (en) 2009-04-28
NO20080408L (no) 2008-03-25
EA200800100A1 (ru) 2008-06-30
JP2008546794A (ja) 2008-12-25
EP1906965A2 (en) 2008-04-09
WO2007002667A2 (en) 2007-01-04
IL188050A0 (en) 2008-03-20
RS54206B1 (en) 2015-12-31
HUE025476T2 (en) 2016-02-29
US20070010524A1 (en) 2007-01-11
WO2007002667A3 (en) 2007-05-10
PT1906965E (pt) 2015-09-03
MX2007015917A (es) 2008-03-10
US20070010523A1 (en) 2007-01-11
CA2612552A1 (en) 2007-01-04
WO2007002293A3 (en) 2007-03-08
SI1906965T1 (sl) 2015-09-30
ZA200800309B (en) 2009-10-28
MA29568B1 (fr) 2008-06-02
AU2006262122B2 (en) 2013-01-17
EP1906965B1 (en) 2015-05-06
DK1906965T3 (en) 2015-08-03
PL1906965T3 (pl) 2015-10-30
NZ564258A (en) 2011-02-25
EA017278B1 (ru) 2012-11-30
HRP20150832T1 (hr) 2015-09-25
EP1906965A4 (en) 2011-05-18
CN101242839B (zh) 2012-11-07
CA2612552C (en) 2015-03-24
ES2543714T3 (es) 2015-08-21
BRPI0612112A2 (pt) 2010-10-19

Similar Documents

Publication Publication Date Title
EA017278B9 (ru) Соединения азаиндазола и способы применения
EP2155203A4 (en) AZAINDAZOLE COMPOUNDS AND METHODS OF USE
WO2007073432A3 (en) Piperidine derivatives and methods of use
WO2007022257A3 (en) Monocyclic and bicyclic compounds and methods of use
JO3319B1 (ar) مركبات 3- (ايميدازول) - بيرازولو (3,4 - b ) بيريدين
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
HK1099206A1 (en) 1-aryl-4-substituted piperazine derivatives and their uses in manufacturing medicaments
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
TW200611695A (en) Pyrrolopyridine derivatives
IL179612A (en) Benzimidazolone carboxylic acid derivatives, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments for the treatment of conditions mediated by 5-ht4 receptor activity
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
UA96277C2 (en) Benzimidazole derivatives
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
MX2008001211A (es) Derivados de bencilpiperazina y su uso medico.
BRPI0918517B8 (pt) composto, composição farmacêutica, e, uso de um composto
UA83868C2 (ru) Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
UA95780C2 (en) Xanthine derivatives as selective hm74a agonists
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
WO2014035967A3 (en) Antagonists of chemokine receptors
TW200734335A (en) Compounds

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU